Enterprise Value
642.5M
Cash
294.6M
Avg Qtr Burn
-39.06M
Short % of Float
26.25%
Insider Ownership
0.39%
Institutional Own.
-
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
IMCIVREE™ (setmelanotide) Details Proopiomelanocortin deficiency (POMC) deficiency obesity | Approved Quarterly sales | |
IMCIVREE™ (setmelanotide) Details Leptin receptor (LEPR) deficiency obesity | Approved Quarterly sales | |
IMCIVREE (Setmelanotide) Details Rare genetic disease, Bardet-Biedl syndrome | Approved Quarterly sales | |
Setmelanotide Details Alström syndrome | NDA FDA meeting | |
Setmelanotide Details Obesity | Phase 3 Data readout | |
Setmelanotide Details Obesity | Phase 2 Interim update |